Literature DB >> 2024974

Inter- and intrasubject variabilities in the pharmacokinetics of rufloxacin after single oral administration to healthy volunteers.

B P Imbimbo1, G Broccali, M Cesana, F Crema, G Attardo-Parrinello.   

Abstract

Rufloxacin is a new long-acting, once-daily quinolone antibacterial agent. We evaluated inter- and intrasubject variations in pharmacokinetics of rufloxacin following oral administration of 400 mg (two capsules) under controlled conditions, at an interval of 2 weeks (periods I and II), to 12 healthy male subjects. Plasma and urine samples were collected up to 48 h after drug administration. Plasma drug levels determined by bioassay were higher than those measured by high-performance liquid chromatography, indicating that one or more active metabolites were formed. Individual high-performance liquid chromatography plasma rufloxacin concentrations were fitted with a one-compartment open model with first-order input. There were considerable variations in the plasma concentration-time profiles among subjects; for example, the elimination half-life in plasma varied from 14.6 to 95.5 h. However, pharmacokinetic parameters calculated for the two periods did not differ significantly. These results suggest that the intrasubject variation in the pharmacokinetics of rufloxacin is usually small in spite of the considerable intersubject variation.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2024974      PMCID: PMC245015          DOI: 10.1128/AAC.35.2.390

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  6 in total

1.  Simplified, accurate method for antibiotic assay of clinical specimens.

Authors:  J V Bennett; J L Brodie; E J Benner; W M Kirby
Journal:  Appl Microbiol       Date:  1966-03

2.  A new criterion for selection of pharmacokinetic multiexponential equations.

Authors:  B P Imbimbo; E Imbimbo; S Daniotti; D Verotta; G Bassotti
Journal:  J Pharm Sci       Date:  1988-09       Impact factor: 3.534

3.  Effect of plasma protein and tissue binding on the biologic half-life of drugs.

Authors:  M Gibaldi; G Levy; P J McNamara
Journal:  Clin Pharmacol Ther       Date:  1978-07       Impact factor: 6.875

4.  Quinolonecarboxylic acids. 2. Synthesis and antibacterial evaluation of 7-oxo-2,3-dihydro-7H-pyrido[1,2,3-de][1,4]benzothiazine-6-carboxylic acids.

Authors:  V Cecchetti; A Fravolini; R Fringuelli; G Mascellani; P Pagella; M Palmioli; G Segre; P Terni
Journal:  J Med Chem       Date:  1987-03       Impact factor: 7.446

5.  A new tricyclic fluoroquinolone, rufloxacin (MF-934), with interesting antibacterial and pharmacokinetic characteristics.

Authors:  G Segre; D Cerretani; D Cerri; L Moltoni
Journal:  Drugs Exp Clin Res       Date:  1988

6.  Rufloxacin (MF-934): in vitro and in vivo antibacterial activity.

Authors:  G Ravizzola; G Pinsi; F Pirali; D Colombrita; I Foresti; L Peroni; A Turano
Journal:  Drugs Exp Clin Res       Date:  1989
  6 in total
  20 in total

1.  Penetration of rufloxacin into the cerebrospinal fluid in patients with inflamed and uninflamed meninges.

Authors:  M V Moretti; S Pauluzzi; M Cesana
Journal:  Antimicrob Agents Chemother       Date:  2000-01       Impact factor: 5.191

Review 2.  Comparative pharmacokinetics and pharmacodynamics of the newer fluoroquinolone antibacterials.

Authors:  A Aminimanizani; P Beringer; R Jelliffe
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

3.  In vivo effects of rufloxacin and ciprofloxacin on T-cell subsets and tumor necrosis factor production in mice infected with Bacteroides fragilis.

Authors:  S V Gollapudi; S K Chuah; T Harvey; H D Thadepalli; H Thadepalli
Journal:  Antimicrob Agents Chemother       Date:  1993-08       Impact factor: 5.191

4.  Ex vivo antibacterial properties of rufloxacin compared with those of norfloxacin in a study with healthy volunteers.

Authors:  L Aguilar; I P Balcabao; P Salvá; M Martín; J Costa; J Prieto; R Dal-ré
Journal:  Antimicrob Agents Chemother       Date:  1996-01       Impact factor: 5.191

5.  In vitro antimycoplasmal activities of rufloxacin and its metabolite MF 922.

Authors:  P M Furneri; G Bisignano; G Cerniglia; G Nicoletti; M Cesana; G Tempera
Journal:  Antimicrob Agents Chemother       Date:  1994-11       Impact factor: 5.191

6.  Biliary excretion of rufloxacin in humans.

Authors:  G Privitera; G Nicastro; B P Imbimbo; M Cesana; M Visconti; F Lombardi; G Tagliabue; E Faleschini; F Colturani; P Franzini
Journal:  Antimicrob Agents Chemother       Date:  1993-12       Impact factor: 5.191

7.  Randomized, double-blind comparison of single-dose regimens of rufloxacin and pefloxacin for acute uncomplicated cystitis in women. French Multicenter Urinary Tract Infection-Rufloxacin Group.

Authors:  A Jardin; M Cesana
Journal:  Antimicrob Agents Chemother       Date:  1995-01       Impact factor: 5.191

8.  Comparative activity of the new fluoroquinolone rufloxacin (MF 934) against clinical isolates of gram-negative and gram-positive bacteria.

Authors:  S M Qadri; Y Ueno; G Postle; D Tullo; J San Pedro
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1993-05       Impact factor: 3.267

9.  Single-dose rufloxacin versus 3-day norfloxacin treatment of uncomplicated cystitis: clinical evaluation and pharmacodynamic considerations.

Authors:  G Del Río; F Dalet; L Aguilar; J Caffaratti; R Dal-Ré
Journal:  Antimicrob Agents Chemother       Date:  1996-02       Impact factor: 5.191

10.  Multiple-dose pharmacokinetics and safety of rufloxacin in normal volunteers.

Authors:  J C Kisicki; R S Griess; C L Ott; G M Cohen; R J McCormack; W M Troetel; B P Imbimbo
Journal:  Antimicrob Agents Chemother       Date:  1992-06       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.